Phase 2/3Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (TeLuRide-008)
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
- Sponsor
- Eikon Therapeutics (Industry)
- Enrolment
- 750 planned
- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous); Stage 4 NSCLC
- Interventions
- EIK1001; Pembrolizumab (KEYTRUDA®); Placebo; Paclitaxel + Carboplatin; Nab-paclitaxel + Carboplatin; Pemetrexed + Cisplatin /Carboplatin
- Ages
- adults, older adults
- Registry
- NCT07365319
From the registry
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Primary outcomes
- Progression-free survival (PFS)
- Overall survival (OS)
- Objective Response (OR)